This research project aims to employ advanced medical statistics methodology to develop a novel Personalised Approach to Chemotherapy Treatment for Ewing’s Sarcoma (PACT-ES). PACT-ES will investigate the longitudinal relationship between dose-reductions/delays in chemotherapy and multiple side effects, and their impact on survival outcomes.
This study aims to develop a user-friendly prediction tool to assist the multidisciplinary team in the decision-making process on INDIvidualized loCAl Therapy for patients with Ewing Sarcoma (INDICATES).
The PERSARC app represents an informative support tool for the dynamic prediction of overall survival (OS) and local recurrence (LR) in high-grade Soft-Tissue Sarcomas of the extremity (eSTS), using patient-, tumour- and treatment-related characteristics. It is currently used by many physicians in their daily practice to assess a more realistic prognosis of expected recurrence rates and life expectancy, improving their clinical-based predictive capability. Furthermore, given its established validity, it can serve as a tool for the validation and comparison of new models for OS and/or LR in eSTS.
The aim of this project is to develop a more generalized and user-friendly algorithm to fit a multistate cure model, on top of the current framework of multistate model and mixture cure model. The proposed algorithm will be applied on a study of childhood osteosarcoma as an example.
The aim of PRIME-ROSE is to enable cross-border data sharing by combining the data from DRUP-like trials in Europe. First, it builds synthetic randomized trials resembling a randomized control trial to evaluate clinical benefit. Second, the project plans to design and conduct pragmatic clinical trials, provide implementation data, effectively involve patients, focus on multi-stakeholder collaboration and continuous knowledge transfer and training of DRUP-like trials.
The aim of the KWF-funded study is to compare the wound healing complication rates and local control between the two different treatment schedules in soft tissue sarcomas, as well as the treatment-related burden for patients and the cost-effectiveness of the two regimens.
The aim of this project is to elaborate the use of statistical methods within the long-standing DRUP trial. First, the pooling of information across the different cohorts will be investigated to better analyze the effectiveness of targeted therapy in DRUP. Secondly, the absence of a control group shall be addressed by examining the application of survival models with historical data.
The aims of the this project are: (i) to evaluate the diagnostic value and accuracy of current pathological techniques in the diagnosis of solid pediatric tumors; (ii) to investigate the prognostic value of molecular aberrations in (non-high-risk) neuroblastoma to improve current risk-stratification and thereby improving outcome of neuroblastoma patients.
The aim of the epiMETA study is to investigate how effective different antiseizure medications are for patients with epilepsy due brain metastases. Using clinical data from patients across the Netherlands, we compare commonly used treatments and study how tumor-directed therapies relate to seizure outcomes.